250 related articles for article (PubMed ID: 21347785)
1. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
[TBL] [Abstract][Full Text] [Related]
2. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
3. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
4. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.
Iwagami Y; Eguchi H; Nagano H; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Tomokuni A; Tomimaru Y; Mori M; Doki Y
Br J Cancer; 2013 Jul; 109(2):502-11. PubMed ID: 23799850
[TBL] [Abstract][Full Text] [Related]
5. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
7. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
[TBL] [Abstract][Full Text] [Related]
8. Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy.
Morinaga S; Nakamura Y; Atsumi Y; Murakawa M; Yamaoku K; Aoyama T; Kobayashi S; Ueno M; Morimoto M; Yokose T; Miyagi Y
Anticancer Res; 2016 Mar; 36(3):1083-8. PubMed ID: 26977002
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
10. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
[TBL] [Abstract][Full Text] [Related]
11. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
12. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
13. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
14. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
16. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Valsecchi ME; Holdbrook T; Leiby BE; Pequignot E; Littman SJ; Yeo CJ; Brody JR; Witkiewicz AK
BMC Cancer; 2012 Mar; 12():104. PubMed ID: 22436573
[TBL] [Abstract][Full Text] [Related]
18. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
[TBL] [Abstract][Full Text] [Related]
19. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
[TBL] [Abstract][Full Text] [Related]
20. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells.
Shrikhande SV; Kleeff J; Kayed H; Keleg S; Reiser C; Giese T; Büchler MW; Esposito I; Friess H
Anticancer Res; 2006; 26(5A):3265-73. PubMed ID: 17094439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
